APO Research
Talk to an analyst

APO RESEARCH · REPORT

Enzalutamide Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Enzalutamide Drugs Market Outlook and Growth Opportunities 2026

27 December 2025208 pages

Choose your research edition.

Industry ResearchEnzalutamide Drugs Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Enzalutamide Drugs Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Enzalutamide Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Enzalutamide Drugs Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Enzalutamide Drugs Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Enzalutamide Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Enzalutamide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Enzalutamide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Enzalutamide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Enzalutamide Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Enzalutamide Drugs market include Yichang Humanwell Pharmaceutical, Shenyang Hongqi Pharmaceutical, PuraCap Pharmaceuticals, Qilu Pharmaceutical, Kelun Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Zydus, Sun Pharma and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Enzalutamide Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Enzalutamide Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Enzalutamide Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Enzalutamide Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Enzalutamide Drugs Segment by Company

Yichang Humanwell Pharmaceutical

Shenyang Hongqi Pharmaceutical

PuraCap Pharmaceuticals

Qilu Pharmaceutical

Kelun Pharmaceutical

Jiangsu Hansoh Pharmaceutical

Zydus

Sun Pharma

Pfizer

Intas Pharmaceuticals

Glenmark Pharma

Beacon pharma

BDR Pharma

Astellas Pharma

Arechar Healthcare

Aprazer Healthcare Pharma

Abbott Laboratories

Enzalutamide Drugs Segment by Type

Tablets

Capsules

Enzalutamide Drugs Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Enzalutamide Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Enzalutamide Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Enzalutamide Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Enzalutamide Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Enzalutamide Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Enzalutamide Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Enzalutamide Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Enzalutamide Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Enzalutamide Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Enzalutamide Drugs industry.

Chapter 3: Detailed analysis of Enzalutamide Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Enzalutamide Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Enzalutamide Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Enzalutamide Drugs Industry Trends Table 2. Enzalutamide Drugs Industry Drivers Table 3. Enzalutamide Drugs Industry Opportunities and Challenges Table 4. Enzalutamide Drugs Industry Restraints Table 5. Global Enzalutamide Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Enzalutamide Drugs Revenue Share by Company (2021-2026) Table 7. Global Enzalutamide Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Enzalutamide Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Enzalutamide Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Enzalutamide Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Enzalutamide Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Enzalutamide Drugs Company, Product Type & Application Table 13. Global Enzalutamide Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Enzalutamide Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Tablets Table 18. Significant Companies of Capsules Table 19. Global Enzalutamide Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Enzalutamide Drugs Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Enzalutamide Drugs Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Enzalutamide Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Enzalutamide Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Enzalutamide Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Enzalutamide Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Enzalutamide Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Enzalutamide Drugs Sales Value Share by Type (2021-2026) Table 28. Global Enzalutamide Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital and Clinic Table 30. Significant Companies of Retail Pharmacies Table 31. Significant Companies of Other Table 32. Global Enzalutamide Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Enzalutamide Drugs Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Enzalutamide Drugs Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Enzalutamide Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Enzalutamide Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Enzalutamide Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Enzalutamide Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Enzalutamide Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Enzalutamide Drugs Sales Value Share by Application (2021-2026) Table 41. Global Enzalutamide Drugs Sales Value Share by Application (2027-2032) Table 42. Global Enzalutamide Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Enzalutamide Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global Enzalutamide Drugs Sales Market Share by Region (2021-2026) Table 45. Global Enzalutamide Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global Enzalutamide Drugs Sales Market Share by Region (2027-2032) Table 47. Global Enzalutamide Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Enzalutamide Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Enzalutamide Drugs Sales Value Share by Region (2021-2026) Table 50. Global Enzalutamide Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Enzalutamide Drugs Sales Value Share by Region (2027-2032) Table 52. Global Enzalutamide Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Enzalutamide Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Enzalutamide Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Enzalutamide Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Enzalutamide Drugs Sales by Country (2021-2026) & (K Units) Table 57. Global Enzalutamide Drugs Sales Market Share by Country (2021-2026) Table 58. Global Enzalutamide Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global Enzalutamide Drugs Sales Market Share by Country (2027-2032) Table 60. Global Enzalutamide Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Enzalutamide Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Enzalutamide Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Enzalutamide Drugs Sales Value Market Share by Country (2027-2032) Table 64. Yichang Humanwell Pharmaceutical Company Information Table 65. Yichang Humanwell Pharmaceutical Business Overview Table 66. Yichang Humanwell Pharmaceutical Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Yichang Humanwell Pharmaceutical Enzalutamide Drugs Product Portfolio Table 68. Yichang Humanwell Pharmaceutical Recent Development Table 69. Shenyang Hongqi Pharmaceutical Company Information Table 70. Shenyang Hongqi Pharmaceutical Business Overview Table 71. Shenyang Hongqi Pharmaceutical Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Shenyang Hongqi Pharmaceutical Enzalutamide Drugs Product Portfolio Table 73. Shenyang Hongqi Pharmaceutical Recent Development Table 74. PuraCap Pharmaceuticals Company Information Table 75. PuraCap Pharmaceuticals Business Overview Table 76. PuraCap Pharmaceuticals Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. PuraCap Pharmaceuticals Enzalutamide Drugs Product Portfolio Table 78. PuraCap Pharmaceuticals Recent Development Table 79. Qilu Pharmaceutical Company Information Table 80. Qilu Pharmaceutical Business Overview Table 81. Qilu Pharmaceutical Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Qilu Pharmaceutical Enzalutamide Drugs Product Portfolio Table 83. Qilu Pharmaceutical Recent Development Table 84. Kelun Pharmaceutical Company Information Table 85. Kelun Pharmaceutical Business Overview Table 86. Kelun Pharmaceutical Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Kelun Pharmaceutical Enzalutamide Drugs Product Portfolio Table 88. Kelun Pharmaceutical Recent Development Table 89. Jiangsu Hansoh Pharmaceutical Company Information Table 90. Jiangsu Hansoh Pharmaceutical Business Overview Table 91. Jiangsu Hansoh Pharmaceutical Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Jiangsu Hansoh Pharmaceutical Enzalutamide Drugs Product Portfolio Table 93. Jiangsu Hansoh Pharmaceutical Recent Development Table 94. Zydus Company Information Table 95. Zydus Business Overview Table 96. Zydus Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Zydus Enzalutamide Drugs Product Portfolio Table 98. Zydus Recent Development Table 99. Sun Pharma Company Information Table 100. Sun Pharma Business Overview Table 101. Sun Pharma Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Sun Pharma Enzalutamide Drugs Product Portfolio Table 103. Sun Pharma Recent Development Table 104. Pfizer Company Information Table 105. Pfizer Business Overview Table 106. Pfizer Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Pfizer Enzalutamide Drugs Product Portfolio Table 108. Pfizer Recent Development Table 109. Intas Pharmaceuticals Company Information Table 110. Intas Pharmaceuticals Business Overview Table 111. Intas Pharmaceuticals Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Intas Pharmaceuticals Enzalutamide Drugs Product Portfolio Table 113. Intas Pharmaceuticals Recent Development Table 114. Glenmark Pharma Company Information Table 115. Glenmark Pharma Business Overview Table 116. Glenmark Pharma Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Glenmark Pharma Enzalutamide Drugs Product Portfolio Table 118. Glenmark Pharma Recent Development Table 119. Beacon pharma Company Information Table 120. Beacon pharma Business Overview Table 121. Beacon pharma Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Beacon pharma Enzalutamide Drugs Product Portfolio Table 123. Beacon pharma Recent Development Table 124. BDR Pharma Company Information Table 125. BDR Pharma Business Overview Table 126. BDR Pharma Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. BDR Pharma Enzalutamide Drugs Product Portfolio Table 128. BDR Pharma Recent Development Table 129. Astellas Pharma Company Information Table 130. Astellas Pharma Business Overview Table 131. Astellas Pharma Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Astellas Pharma Enzalutamide Drugs Product Portfolio Table 133. Astellas Pharma Recent Development Table 134. Arechar Healthcare Company Information Table 135. Arechar Healthcare Business Overview Table 136. Arechar Healthcare Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Arechar Healthcare Enzalutamide Drugs Product Portfolio Table 138. Arechar Healthcare Recent Development Table 139. Aprazer Healthcare Pharma Company Information Table 140. Aprazer Healthcare Pharma Business Overview Table 141. Aprazer Healthcare Pharma Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Aprazer Healthcare Pharma Enzalutamide Drugs Product Portfolio Table 143. Aprazer Healthcare Pharma Recent Development Table 144. Abbott Laboratories Company Information Table 145. Abbott Laboratories Business Overview Table 146. Abbott Laboratories Enzalutamide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Abbott Laboratories Enzalutamide Drugs Product Portfolio Table 148. Abbott Laboratories Recent Development Table 149. Key Raw Materials Table 150. Raw Materials Key Suppliers Table 151. Enzalutamide Drugs Distributors List Table 152. Enzalutamide Drugs Customers List Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Enzalutamide Drugs Product Image Figure 2. Global Enzalutamide Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Enzalutamide Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Enzalutamide Drugs Sales (2021-2032) & (K Units) Figure 5. Global Enzalutamide Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Enzalutamide Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Tablets Image Figure 10. Capsules Image Figure 11. Global Enzalutamide Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Enzalutamide Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Enzalutamide Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Enzalutamide Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Enzalutamide Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Enzalutamide Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospital and Clinic Image Figure 18. Retail Pharmacies Image Figure 19. Other Image Figure 20. Global Enzalutamide Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Enzalutamide Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Enzalutamide Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Enzalutamide Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Enzalutamide Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Enzalutamide Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Enzalutamide Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Enzalutamide Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Enzalutamide Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Enzalutamide Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Enzalutamide Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Enzalutamide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Enzalutamide Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Enzalutamide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Enzalutamide Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Enzalutamide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Enzalutamide Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Enzalutamide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Enzalutamide Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Enzalutamide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Enzalutamide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Enzalutamide Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Enzalutamide Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets
  • Capsules
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Yichang Humanwell Pharmaceutical
  • Shenyang Hongqi Pharmaceutical
  • PuraCap Pharmaceuticals
  • Qilu Pharmaceutical
  • Kelun Pharmaceutical
  • Jiangsu Hansoh Pharmaceutical
  • Zydus
  • Sun Pharma
  • Pfizer
  • Intas Pharmaceuticals
  • Glenmark Pharma
  • Beacon pharma
  • BDR Pharma
  • Astellas Pharma
  • Arechar Healthcare
  • Aprazer Healthcare Pharma
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Enzalutamide Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Enzalutamide Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Enzalutamide Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Enzalutamide Drugs Market Dynamics
  1. 2.1 Enzalutamide Drugs Industry Trends
  2. 2.2 Enzalutamide Drugs Industry Drivers
  3. 2.3 Enzalutamide Drugs Industry Opportunities and Challenges
  4. 2.4 Enzalutamide Drugs Industry Restraints
3 Enzalutamide Drugs Market by Company
  1. 3.1 Global Enzalutamide Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Enzalutamide Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Enzalutamide Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Enzalutamide Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Enzalutamide Drugs Company Ranking (2024-2026)
  6. 3.6 Global Enzalutamide Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Enzalutamide Drugs Company Product Type and Application
  8. 3.8 Global Enzalutamide Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Enzalutamide Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Enzalutamide Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Enzalutamide Drugs Market by Type
  1. 4.1 Enzalutamide Drugs Type Introduction
  2. 4.1.1 Tablets
  3. 4.1.2 Capsules
  4. 4.2 Global Enzalutamide Drugs Sales Volume by Type
  5. 4.2.1 Global Enzalutamide Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Enzalutamide Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Enzalutamide Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Enzalutamide Drugs Sales Value by Type
  9. 4.3.1 Global Enzalutamide Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Enzalutamide Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Enzalutamide Drugs Sales Value Share by Type (2021-2032)
5 Enzalutamide Drugs Market by Application
  1. 5.1 Enzalutamide Drugs Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Enzalutamide Drugs Sales Volume by Application
  6. 5.2.1 Global Enzalutamide Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Enzalutamide Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Enzalutamide Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Enzalutamide Drugs Sales Value by Application
  10. 5.3.1 Global Enzalutamide Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Enzalutamide Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Enzalutamide Drugs Sales Value Share by Application (2021-2032)
6 Enzalutamide Drugs Regional Sales and Value Analysis
  1. 6.1 Global Enzalutamide Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Enzalutamide Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Enzalutamide Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Enzalutamide Drugs Sales by Region (2027-2032)
  5. 6.3 Global Enzalutamide Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Enzalutamide Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Enzalutamide Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Enzalutamide Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Enzalutamide Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Enzalutamide Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Enzalutamide Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Enzalutamide Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Enzalutamide Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Enzalutamide Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Enzalutamide Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Enzalutamide Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Enzalutamide Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Enzalutamide Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Enzalutamide Drugs Sales Value Share by Country, 2025 VS 2032
7 Enzalutamide Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Enzalutamide Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Enzalutamide Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Enzalutamide Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Enzalutamide Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Enzalutamide Drugs Sales by Country (2027-2032)
  6. 7.4 Global Enzalutamide Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Enzalutamide Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Enzalutamide Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Enzalutamide Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Enzalutamide Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Enzalutamide Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yichang Humanwell Pharmaceutical
  2. 8.1.1 Yichang Humanwell Pharmaceutical Company Information
  3. 8.1.2 Yichang Humanwell Pharmaceutical Business Overview
  4. 8.1.3 Yichang Humanwell Pharmaceutical Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Yichang Humanwell Pharmaceutical Enzalutamide Drugs Product Portfolio
  6. 8.1.5 Yichang Humanwell Pharmaceutical Recent Developments
  7. 8.2 Shenyang Hongqi Pharmaceutical
  8. 8.2.1 Shenyang Hongqi Pharmaceutical Company Information
  9. 8.2.2 Shenyang Hongqi Pharmaceutical Business Overview
  10. 8.2.3 Shenyang Hongqi Pharmaceutical Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Shenyang Hongqi Pharmaceutical Enzalutamide Drugs Product Portfolio
  12. 8.2.5 Shenyang Hongqi Pharmaceutical Recent Developments
  13. 8.3 PuraCap Pharmaceuticals
  14. 8.3.1 PuraCap Pharmaceuticals Company Information
  15. 8.3.2 PuraCap Pharmaceuticals Business Overview
  16. 8.3.3 PuraCap Pharmaceuticals Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 PuraCap Pharmaceuticals Enzalutamide Drugs Product Portfolio
  18. 8.3.5 PuraCap Pharmaceuticals Recent Developments
  19. 8.4 Qilu Pharmaceutical
  20. 8.4.1 Qilu Pharmaceutical Company Information
  21. 8.4.2 Qilu Pharmaceutical Business Overview
  22. 8.4.3 Qilu Pharmaceutical Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Qilu Pharmaceutical Enzalutamide Drugs Product Portfolio
  24. 8.4.5 Qilu Pharmaceutical Recent Developments
  25. 8.5 Kelun Pharmaceutical
  26. 8.5.1 Kelun Pharmaceutical Company Information
  27. 8.5.2 Kelun Pharmaceutical Business Overview
  28. 8.5.3 Kelun Pharmaceutical Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Kelun Pharmaceutical Enzalutamide Drugs Product Portfolio
  30. 8.5.5 Kelun Pharmaceutical Recent Developments
  31. 8.6 Jiangsu Hansoh Pharmaceutical
  32. 8.6.1 Jiangsu Hansoh Pharmaceutical Company Information
  33. 8.6.2 Jiangsu Hansoh Pharmaceutical Business Overview
  34. 8.6.3 Jiangsu Hansoh Pharmaceutical Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Hansoh Pharmaceutical Enzalutamide Drugs Product Portfolio
  36. 8.6.5 Jiangsu Hansoh Pharmaceutical Recent Developments
  37. 8.7 Zydus
  38. 8.7.1 Zydus Company Information
  39. 8.7.2 Zydus Business Overview
  40. 8.7.3 Zydus Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Zydus Enzalutamide Drugs Product Portfolio
  42. 8.7.5 Zydus Recent Developments
  43. 8.8 Sun Pharma
  44. 8.8.1 Sun Pharma Company Information
  45. 8.8.2 Sun Pharma Business Overview
  46. 8.8.3 Sun Pharma Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sun Pharma Enzalutamide Drugs Product Portfolio
  48. 8.8.5 Sun Pharma Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Enzalutamide Drugs Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Intas Pharmaceuticals
  56. 8.10.1 Intas Pharmaceuticals Company Information
  57. 8.10.2 Intas Pharmaceuticals Business Overview
  58. 8.10.3 Intas Pharmaceuticals Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Intas Pharmaceuticals Enzalutamide Drugs Product Portfolio
  60. 8.10.5 Intas Pharmaceuticals Recent Developments
  61. 8.11 Glenmark Pharma
  62. 8.11.1 Glenmark Pharma Company Information
  63. 8.11.2 Glenmark Pharma Business Overview
  64. 8.11.3 Glenmark Pharma Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Glenmark Pharma Enzalutamide Drugs Product Portfolio
  66. 8.11.5 Glenmark Pharma Recent Developments
  67. 8.12 Beacon pharma
  68. 8.12.1 Beacon pharma Company Information
  69. 8.12.2 Beacon pharma Business Overview
  70. 8.12.3 Beacon pharma Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Beacon pharma Enzalutamide Drugs Product Portfolio
  72. 8.12.5 Beacon pharma Recent Developments
  73. 8.13 BDR Pharma
  74. 8.13.1 BDR Pharma Company Information
  75. 8.13.2 BDR Pharma Business Overview
  76. 8.13.3 BDR Pharma Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 BDR Pharma Enzalutamide Drugs Product Portfolio
  78. 8.13.5 BDR Pharma Recent Developments
  79. 8.14 Astellas Pharma
  80. 8.14.1 Astellas Pharma Company Information
  81. 8.14.2 Astellas Pharma Business Overview
  82. 8.14.3 Astellas Pharma Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Astellas Pharma Enzalutamide Drugs Product Portfolio
  84. 8.14.5 Astellas Pharma Recent Developments
  85. 8.15 Arechar Healthcare
  86. 8.15.1 Arechar Healthcare Company Information
  87. 8.15.2 Arechar Healthcare Business Overview
  88. 8.15.3 Arechar Healthcare Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Arechar Healthcare Enzalutamide Drugs Product Portfolio
  90. 8.15.5 Arechar Healthcare Recent Developments
  91. 8.16 Aprazer Healthcare Pharma
  92. 8.16.1 Aprazer Healthcare Pharma Company Information
  93. 8.16.2 Aprazer Healthcare Pharma Business Overview
  94. 8.16.3 Aprazer Healthcare Pharma Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Aprazer Healthcare Pharma Enzalutamide Drugs Product Portfolio
  96. 8.16.5 Aprazer Healthcare Pharma Recent Developments
  97. 8.17 Abbott Laboratories
  98. 8.17.1 Abbott Laboratories Company Information
  99. 8.17.2 Abbott Laboratories Business Overview
  100. 8.17.3 Abbott Laboratories Enzalutamide Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Abbott Laboratories Enzalutamide Drugs Product Portfolio
  102. 8.17.5 Abbott Laboratories Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Enzalutamide Drugs Value Chain Analysis
  2. 9.1.1 Enzalutamide Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Enzalutamide Drugs Sales Mode & Process
  6. 9.2 Enzalutamide Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Enzalutamide Drugs Distributors
  9. 9.2.3 Enzalutamide Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst